Medical University of South Carolina, Charleston, South Carolina, United States - 28 Jul `22Topical rapamycin for vitiligo

Topical rapamycin for vitiligo

Official title: Daily Topical Rapamycin Therapy for the Treatment of Vitiligo

Status: Closed to new participants

Description:

Medical University of South Carolina plans to enroll about 20 participants. Rapamycin, also called sirolimus, reduces immune-cell activity and is being applied to the skin in this study. Researchers hope it will slow the immune attack on melanocytes and support repigmentation. Systemic sirolimus is sold as Rapamune for transplant rejection prevention and another rare condition; topical treatment for vitiligo is experimental. Possible effects include skin irritation, acne-like bumps, mouth sores, and infections. People age 13 and older may qualify. The study is underway but is no longer accepting new participants.

Start date: July 28, 2022

Completion date: December 01, 2027

Organizer: Medical University of South Carolina

Contact: Ahmad Aleisa, MD

Link: https://clinicaltrials.gov/study/NCT05342519

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Topical rapamycin for vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Which therapy has minimal side-effects?

    Dead Sea climatotherapy is a unique and highly effective treatment option for vitiligo, offering a top-tier safety profile and natural therapeutic benefits. Its combination of p...

  • Is there a special diet for vitiligo?

    Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...